Hainan Hailing Product Portfolio: A Responsible First Review

1. What the supplied catalogue says

The bilingual Hainan Hailing product catalogue supplied to this site is dated May 2026. It organizes product entries principally by topical preparations, oral preparations and injection preparations, and also groups entries by therapeutic areas. Anti-infective categories are prominent, alongside other therapeutic areas.

This page intentionally preserves that broad orientation rather than reproducing every product name, strength and packaging entry. A portfolio document can change and may contain market-, legal-entity- or status-sensitive information. For current publicly listed manufacturing scope and the limits of public evidence, see the public evidence and verification boundary.

2. What it can support in a first screen

A prospective partner can use the dosage-form map to state the first decision clearly: whether to explore a topical, oral or injectable route, and whether the intended therapeutic area and presentation warrant a controlled next-step review. For sterile projects, use the dedicated sterile injectable CMO/CDMO orientation; it explains why a platform statement alone is not product readiness.

• Topical: define presentation, target country and public product status to be checked.
• Oral: define dosage form, release characteristics, presentation and intended regulatory route.
• Injectable: define the sterile strategy, presentation, target market and evidence needed before a project decision.

3. What it cannot establish

A name or dosage form in a catalogue does not confirm that the named product is authorised, marketed, supplied, transferable or suitable in a particular jurisdiction. Nor does it establish which legal entity or site would be relevant to a proposal. Product-specific facts must be matched to the current target-market requirements and reviewed under appropriate confidentiality and governance arrangements.

For examples of how dated, product-specific public records should be read without overreach, see Hainan Hailing overseas registration records. A dated public record and a current commercial or regulatory conclusion are different things.

4. Dated public-record cross-checks

The supplied catalogue can be made more useful without turning it into a current offer: match individual entries to a named, dated public record, then retain the record’s original scope. The examples below are intentionally narrow.

• Latamoxef Sodium for Injection: the National Healthcare Security Administration’s GY-YD2024-2 proposed-selection results table records Hainan Hailing Chemipharma with an injectable 0.25 g × 1 presentation within that specified procurement process. Read the dedicated public-record guide for the evidence boundary.
• Luliconazole Cream: Qinghai’s 2024 appendix “Products included in the alternative drug directory” records Luliconazole Cream, cream dosage form, 1% (10 g:100 mg) and 1 tube, with Hainan Hailing Chemipharma named in its producer and agency fields.
• Piperacillin Sodium for Injection: the same Qinghai appendix records Piperacillin Sodium for Injection, injectable dosage form, 2.0 g and 1 vial, with Hainan Hailing Chemipharma named in those same fields.

5. How to start a non-confidential discussion

Before an NDA, a concise portfolio inquiry should identify the public generic name, dosage form, presentation, target market, project stage, intended cooperation model, timing assumption and the decision sought. Do not send patient information, complete formulae, detailed processes, unpublished dossiers or trade secrets in first contact.

For a structured first screen, use the non-confidential CMO/CDMO assessment guide, then contact lyq@cjrf.com with only the relevant non-confidential context.